D-SPECT Series
Digital SPECT cardiology imaging with open-gantry design and 2-minute myocardial perfusion scans
Company profile
Company profile
Spectrum Dynamics Medical is a medical imaging technology company focused on developing advanced digital SPECT (Single Photon Emission Computed Tomography) imaging solutions for nuclear medicine. The company's core innovation centers on the use of CZT (Cadmium Zinc Telluride) solid-state detectors, which provide superior sensitivity, energy resolution, and count rates compared to traditional NaI detectors with Anger-based technology. The company offers two primary product lines: the D-SPECT Series for cardiology applications, featuring an open-gantry design and capable of myocardial perfusion scans in as little as two minutes, and the VERITON-CT Series, the first ring-shaped SPECT/CT system offering 360-degree total body digital imaging with an 80cm bore size. Both systems leverage CZT technology to enable dynamic imaging capabilities and improved diagnostic accuracy. Spectrum Dynamics serves hospitals, clinics, and cardiology centers worldwide, with a particular focus on meeting the clinical needs and workflow demands of modern diagnostic imaging departments. The company's technology represents a paradigm shift in nuclear medicine scanner design, offering faster scan times, improved patient comfort, and enhanced diagnostic capabilities including emission-based attenuation correction and flow reserve calculation. With operations spanning multiple continents including a dedicated China division, Spectrum Dynamics continues to advance the field of nuclear medicine imaging through its innovative digital SPECT platforms.
Company description Spectrum Dynamics Medical official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Embedded · On Premise deployment with recorded integration context.
Company milestones
Tomer Gabay appointed as new Chief Executive Officer
Partnerships
No partners are currently listed.
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Digital SPECT cardiology imaging with open-gantry design and 2-minute myocardial perfusion scans
Emission-based attenuation correction technology using patient's own SPECT data
First ring-shaped 360° total body digital SPECT/CT with 18-minute full body hybrid scanning
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · Jul 23, 2026
A deep-learning noise reduction algorithm outperforms the spatial filters previously required for bone SPECT on a high-speed whole-body 360° CZT-camera.EJNMMI research · Dec 31, 2025
Assessment of sestamibi CZT-SPECT reconstructed using deep-learning-based virtual attenuation correction maps according to coronary artery territory and with comparison to rubidium-PET.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · Jul 1, 2025
Ultra-fast whole-body bone tomoscintigraphies achieved with a high-sensitivity 360° CZT camera and a dedicated deep-learning noise reduction algorithm.European journal of nuclear medicine and molecular imaging · Apr 1, 2024
Accuracy and Reproducibility of Myocardial Blood Flow Quantification by Single Photon Emission Computed Tomography Imaging in Patients With Known or Suspected Coronary Artery Disease.Circulation. Cardiovascular imaging · Jun 1, 2022
Quantification of myocardial blood flow by CZT-SPECT with motion correction and comparison with 15O-water PET.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · Aug 1, 2021
Clinical validation
No linked records are currently available.
Regulatory
K254001 · 510k · Jan 13, 2026
TruSPECT Processing StationK253532 · 510k · Dec 30, 2025
TruSPECT Radiological Image Processing StationK212230 · 510k · Aug 16, 2021
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Myocardial perfusion scan as fast as 2 minutes stress/4 minutes rest
18-minute total body hybrid scan in 3D, 3 minutes per bed position for bone SPECT/CT
Emission-based attenuation correction for conclusive findings without external radiation source
Implementation of digital SPECT imaging technology
05 · Leadership
Leadership profiles and professional links from the current Company record.
Tomer Gabay
Chief Executive Officer
Esha Bandyopadhyay
General Counsel and Corporate Secretary
Xin Ma
Head of China Operations
Ruthie Ben-Kish
VP of Research & Development and Program Management Officer
Shlomi Aloya
VP of Customer Support
Dalia Shiti
VP of Clinical Applications
Nilda Rivera
Senior Director of Product Marketing
Ayelet Dekel
VP of Human Resources
06 · Company updates
Recent articles published on Spectrum Dynamics Medical's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.